Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 300 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
Summary
- Trilaciclib (Cosela) is a drug indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
- The systematic review and meta-analysis document on Cosela showed that it significantly reduced the occurrence of severe neutropenia, febrile neutropenia, anemia and shortened duration of severe neutropenia during treatment.
- This analysis included four randomized controlled trials involving 345 patients with either small cell lung cancer or breast cancer who were treated with Trilaciclib plus chemotherapy compared to those receiving only chemotherapy.
- Patients treated with Trilaciclib had lower rates of erythropoiesis-stimulating agents use (4.03% vs. 11.8%), granulocyte colony-stimulating factor use (37.0% vs. 53.5%), and red blood cell transfusions (19.8% vs. 29.9%) than those not given this medication before their chemotherapy regimens.
- There was no negative impact observed from using Trilaciclib on overall response rate, overall survival, and progress-free survival outcomes as compared to standard treatments alone; indicating its effectiveness does not compromise other clinical benefits associated with traditional chemotherapies used in treating malignant cancers among adults.
- Trilaciclib did not increase the risk for other common adverse events such as diarrhea, fatigue, nausea or vomiting which are often seen due to chemotherapy treatments suggesting its safety profile is acceptable for usage among adult patient population undergoing specific types of chemotherapeutic regimens against malignancies like SCLC or breast cancer.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cosela (trilaciclib) Prescribing Information. | 2023 | G1 Therapeutics, Inc. Durham, NC |